DE602004012117T2 - Neue zusammensetzungen von sildenafil-freier base - Google Patents

Neue zusammensetzungen von sildenafil-freier base Download PDF

Info

Publication number
DE602004012117T2
DE602004012117T2 DE602004012117T DE602004012117T DE602004012117T2 DE 602004012117 T2 DE602004012117 T2 DE 602004012117T2 DE 602004012117 T DE602004012117 T DE 602004012117T DE 602004012117 T DE602004012117 T DE 602004012117T DE 602004012117 T2 DE602004012117 T2 DE 602004012117T2
Authority
DE
Germany
Prior art keywords
less
sildenafil
composition
free base
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004012117T
Other languages
German (de)
English (en)
Other versions
DE602004012117D1 (de
Inventor
Tuula A. Malvern RYDE
Douglas C. Gilbertsville HOVEY
H. William Bryn Mawr BOSCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of DE602004012117D1 publication Critical patent/DE602004012117D1/de
Application granted granted Critical
Publication of DE602004012117T2 publication Critical patent/DE602004012117T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
DE602004012117T 2003-07-23 2004-07-23 Neue zusammensetzungen von sildenafil-freier base Expired - Lifetime DE602004012117T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48910103P 2003-07-23 2003-07-23
US489101P 2003-07-23
PCT/US2004/019106 WO2005013937A2 (en) 2003-07-23 2004-07-23 Novel compositions of sildenafil free base

Publications (2)

Publication Number Publication Date
DE602004012117D1 DE602004012117D1 (de) 2008-04-10
DE602004012117T2 true DE602004012117T2 (de) 2009-02-26

Family

ID=34135095

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004012117T Expired - Lifetime DE602004012117T2 (de) 2003-07-23 2004-07-23 Neue zusammensetzungen von sildenafil-freier base

Country Status (8)

Country Link
US (1) US20050042177A1 (https=)
EP (1) EP1658053B1 (https=)
JP (1) JP4860469B2 (https=)
AT (1) ATE387186T1 (https=)
CA (1) CA2533163A1 (https=)
DE (1) DE602004012117T2 (https=)
ES (1) ES2302035T3 (https=)
WO (1) WO2005013937A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP1471887B1 (en) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
ATE387203T1 (de) 2004-01-05 2008-03-15 Teva Pharma Prozesse zur herstellung von sildenafil-base und zitratsalz
KR20070034524A (ko) 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
AU2012201630B8 (en) * 2004-12-31 2014-03-06 Iceutica Pty Ltd NanoParticle Composition(s) and Method for Synthesis Thereof
EP1830824B1 (en) * 2004-12-31 2016-01-13 Iceutica Pty Ltd. Nanoparticle composition and methods for synthesis thereof
WO2006074443A2 (en) * 2005-01-07 2006-07-13 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
CN101262860A (zh) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
WO2008073068A1 (en) 2005-06-08 2008-06-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
ES2335608T3 (es) * 2005-06-09 2010-03-30 Elan Pharma International Limited Formulaciones de ebistina nanoparticuladas.
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
EP1843770B1 (en) * 2005-08-29 2008-06-18 Teva Pharmaceutical Industries Ltd Solid particulate tadalafil having a bimodal particle size distribution
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
CA2633570A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
CA2635531C (en) 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
EP2051702A1 (en) * 2007-01-22 2009-04-29 Novavax, Inc. Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
AU2009225719A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
AU2010261510A1 (en) * 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
CN102711749A (zh) 2009-11-05 2012-10-03 莱西肯医药有限公司 用于癌症治疗的色氨酸羟化酶抑制剂
CN102753168A (zh) 2010-02-10 2012-10-24 莱西肯医药有限公司 用于治疗转移性骨病的色氨酸羟化酶抑制剂
WO2011156405A2 (en) * 2010-06-07 2011-12-15 Novadel Pharma Inc. Oral spray formulations and methods for administration of sildenafil
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102127182B (zh) * 2010-12-23 2012-07-04 南京医科大学 用于检测pde-5抑制剂的磁性分子印记聚合物的制备方法
BR112013020237A2 (pt) * 2011-02-11 2021-03-16 Ctc Bio, Inc. Processo para preparar um filme contendo base livre de sildenafila e filme contendo base livre de sildenafila
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
EP3024471B1 (en) 2013-07-22 2019-10-30 Université du Québec à Chicoutimi Use of plant extracts against herpes simplex virus
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
KR101778688B1 (ko) 2016-05-31 2017-09-15 한양대학교 에리카산학협력단 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제
EP3576741A1 (en) 2017-02-02 2019-12-11 Dukebox SP. Z O.O. A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
EP3731870B1 (en) 2017-12-26 2025-11-12 Liqmeds Limited Liquid oral formulations for pde v inhibitors
GR1009643B (el) * 2018-06-25 2019-11-12 Arvo Μονοπροσωπη Ι.Κ.Ε. Νεες συνθεσεις φαρμακευτικων σκευασματων σιλδεναφιλης μειωμενης περιεκτικοτητας σε δραστικη ουσια και νεες χρησεις τους
CN112972404A (zh) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 一种西地那非冻干口腔崩解片及其制备方法
CN112972405B (zh) * 2019-12-02 2022-12-27 北京兴源联合医药科技有限公司 一种他达拉非冻干口腔崩解片及其制备方法
ES2984690T3 (es) 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2023037394A1 (en) * 2021-09-13 2023-03-16 Amman Pharmaceutical Industries Company A pharmaceutical composition of sildenafil and a formulation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
EP1237538A2 (en) * 1999-11-18 2002-09-11 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
JP2003534377A (ja) * 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil

Also Published As

Publication number Publication date
WO2005013937A3 (en) 2005-06-16
DE602004012117D1 (de) 2008-04-10
WO2005013937A2 (en) 2005-02-17
EP1658053A2 (en) 2006-05-24
JP4860469B2 (ja) 2012-01-25
EP1658053B1 (en) 2008-02-27
ATE387186T1 (de) 2008-03-15
ES2302035T3 (es) 2008-07-01
CA2533163A1 (en) 2005-02-17
JP2006528176A (ja) 2006-12-14
US20050042177A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
DE602004012117T2 (de) Neue zusammensetzungen von sildenafil-freier base
DE60222160T2 (de) Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
DE60319073T2 (de) Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
US7390505B2 (en) Nanoparticulate topiramate formulations
JP4787165B2 (ja) 表面安定剤としてペプチドを有するナノ粒子組成物
DE60309300T2 (de) Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US9101549B2 (en) Nanoparticulate megestrol formulations
JP4838514B2 (ja) 低粘度液体剤形
JP2005529911A (ja) ナノ粒子ナイスタチン製剤
JP2009518300A (ja) モメタゾン組成物ならびにその作製方法および使用方法
JP2010248220A (ja) ナノ粒子メゲストロール製剤
JP2006514688A (ja) ゲル安定化ナノパーティクル活性物質組成物
JP2009508859A (ja) ナノ粒子アリピプラゾール製剤
JP2023062070A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2008546796A (ja) ナノ微粒子メゲストロール製剤
US20100226989A1 (en) Nanoparticulate megestrol formulations

Legal Events

Date Code Title Description
8364 No opposition during term of opposition